A Phase II clinical study to evaluate the safety and tolerability of a repurposed FDA-approved drug for novel application in Alzheimer’s disease

The Knight Initiative supports efforts to repurpose FDA-approved drugs for treating Alzheimer’s disease (AD), accelerating the development of potential therapies. This strategic translational grant builds on extensive patient data and recent studies from multiple institutions that identified a promising link between certain existing drugs and a reduced risk of AD. A phase 2 clinical trial is now underway to evaluate the safety and efficacy of this approach in individuals with Alzheimer's disease amyloid positivity, aiming to develop a treatment that could slow or prevent cognitive decline in AD patients.